The effect of terazosin on functional bladder outlet obstruction in women: a pilot study.

Abstract

PURPOSE:

We assessed the effect of terazosin (Hytrin(R)) on functional bladder outlet obstruction in women.

MATERIALS AND METHODS:

Functional bladder outlet obstruction was defined as a maximum flow rate of less than 12 ml per second combined with a detrusor pressure at maximum flow rate of more than 20 cm H2O in pressure flow studies in the absence of neurological disorders or mechanical causes. In a prospective pilot study 15 women with functional bladder outlet obstruction were treated with terazosin. Terazosin was initiated at 1 mg daily and gradually increased to the maintenance dose of 5 mg daily during 2 weeks. Symptoms and urodynamic parameters were assessed before and 3 to 4 weeks after the initiation of alpha-blocker therapy.

RESULTS:

While on terazosin, voiding symptoms subjectively improved greater than 50% in 10 of the 15 women (p = 0.002). Median maximum urethral closure pressure at rest decreased significantly from 98 to 70 cm H2O (p = 0.001), median maximum detrusor pressure decreased from 45 to 35 cm H2O (p = 0.008), median detrusor pressure at maximum flow decreased from 34 to 27 ml per second and median post-void residual urine decreased from 120 to 40 ml (p = 0.006 and 0.002, respectively). There was a significant increase in the median maximum flow rate from 9 to 20 ml per second and in median voided volume from 300 to 340 ml (p = 0.0005 and 0.021, respectively). Storage symptoms, functional urethral length and maximum cystometric capacity did not change significantly with alpha-blocker therapy (p > 0.05). Overall terazosin resulted in a significant improvement in symptoms and urodynamic parameters in 10 of the 15 women (67%).

CONCLUSIONS:

Terazosin had a significant symptomatic and urodynamic effect in two-thirds of our patients. These results suggest that terazosin may be an effective treatment option in women with voiding dysfunction due to functional bladder outlet obstruction.

• Authors: Thomas M Kessler, Urs E Studer, Fiona C Burkhard
• Journal: The Journal of urology (J Urol) Vol. 176 Issue 4 Pt 1 Pg. 1487-92 (Oct 2006) ISSN: 0022-5347 [Print] United States
• PMID: 16952666 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Adrenergic alpha-Antagonists
• Terazosin
• Prazosin

Topics

• Adrenergic alpha-Antagonists (therapeutic use)
• Adult
• Female
• Humans
• Middle Aged
• Pilot Projects
• Prazosin (analogs & derivatives, therapeutic use)
• Prospective Studies
• Treatment Outcome
• Urinary Bladder (physiopathology)
• Urinary Bladder Neck Obstruction (drug therapy, physiopathology)
• Urination (physiology)
• Urodynamics